Radiopharmaceutical imaging of neurodegenerative diseases
Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.
1. A method for detecting or ruling out multiple neurodegenerative diseased states or pathologic processes in a patient comprising:
administering an effective amount of 18 F-AV-45 to a patient, wherein β-amyloid is associated with a first diseased state or pathologic process;
acquiring an image to detect the presence or absence of β-amyloid plaque in the cortical regions of the brain of the patient;
administering an effective amount of 18 F-AV-133, wherein dopaminergic degeneration of nigrostriatal neurons is associated with a second diseased state or pathologic process;
acquiring an image to detect dopaminergic degeneration of nigrostriatal neurons in the striatal regions of the brain of the patient;
detecting the presence or absence of the first diseased state or pathologic process; and
detecting the presence or absence of the second diseased state or pathologic process.
2. The method of claim 1 , wherein the effective amount of 18 F-AV-45 comprises from about 0.1 to about 20 mCi.
3. The method of claim 1 , wherein the effective amount of 18 F-AV-45 comprises about 10 mCi.
4. The method of claim 1 , wherein the effective amount of 18 F-AV-133 comprises from about 0.1 to about 20 mCi.
5. The method of claim 1 , wherein the effective amount of 18 F-AV-133 comprises about 10 mCi.
6. The method of claim 1 , wherein the first diseased state is at least one of dementia, cognitive impairment, Alzheimer's Disease (AD), Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), Vascular Dementia (VaD), and combinations thereof.
7. The method of claim 1 , wherein the second diseased state is at least one of dementia, cognitive impairment, Alzheimer's Disease (AD), Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), Vascular Dementia (VaD), and combinations thereof.
8. The method of claim 1 , wherein the step of administering the radiopharmaceutical targeted to β-amyloid plaque and the step of administering the radiopharmaceutical targeted to nigrostriatal neurons are performed concurrently.
9. The method of claim 1 , wherein the step of acquiring an image to detect the presence or absence of the β-amyloid plaque in the cortical regions of the brain of the patient and the step of acquiring an image to detect the dopaminergic degeneration of nigrostriatal neurons in the striatal regions of the brain of the patient are performed concurrently.
10. The method of claim 1 , wherein the steps of acquiring images comprise positron emission tomography (PET) imaging, single photon emission computed tomography (SPECT) imaging, PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MRI), SPECT with concurrent CT imaging (SPECT/CT), or a combination thereof.
11. The method of claim 1 , further comprising the step of normalizing the image intensity of the acquired images to the cerebellum of the brain of the patient.
12. The method of claim 1 , wherein the steps of detecting the first diseased state or pathologic process and detecting the second diseased state or pathologic process are performed concurrently.